Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SCOPE
NCT06895486Phase 2Recruiting
- Sponsor
- PATH
- Start
- Nov 2025
- Primary completion
- Dec 2026
- Modality
- Live Attenuated Vaccines, Live Biotherapeutic Products
- Countries
- 1
01
Overview
A Phase 2 trial of Novel oral polio vaccine type 1, nOPV2 in poliomyelitis, sponsored by PATH. Started Nov 2025; status: recruiting.
02
Drugs
Novel oral polio vaccine type 1nOPV2
03
Conditions
poliomyelitis
Beyond the preview
Go deeper on NCT06895486.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06895486.